GR1000989B - Μεθοδος παρασκευης συνθεσεως για θεραπεια οστεοπορωσης και ορμονικης ανισορροπιας. - Google Patents

Μεθοδος παρασκευης συνθεσεως για θεραπεια οστεοπορωσης και ορμονικης ανισορροπιας.

Info

Publication number
GR1000989B
GR1000989B GR910100192A GR910100192A GR1000989B GR 1000989 B GR1000989 B GR 1000989B GR 910100192 A GR910100192 A GR 910100192A GR 910100192 A GR910100192 A GR 910100192A GR 1000989 B GR1000989 B GR 1000989B
Authority
GR
Greece
Prior art keywords
estrogen
osteoporosis
preparing
composition
fluoride ion
Prior art date
Application number
GR910100192A
Other languages
English (en)
Other versions
GR910100192A (en
Inventor
G Grodberg Marcus
Original Assignee
Colgate Palmolive Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Colgate Palmolive Co filed Critical Colgate Palmolive Co
Publication of GR910100192A publication Critical patent/GR910100192A/el
Publication of GR1000989B publication Critical patent/GR1000989B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Ενα φάρμακο για παροχή ιόντος φθορίου για την πρόληψη και θεραπεία ασθένειας απώλειας οστού, μαζί με μία ουσία που περιέχει οιστρογόνο όχι μόνο για θεραπεία ορμονικής ανισορροπίας αλλά και για να λαμβάνεται πιο πλεονεκτική χρήση ιόντος φθορίου στο σώμα. Η δοσολογία είναι ένας τροχίσκος, δισκίο ή κάψουλα, που περιέχει από 20 έως 100 χιλιοστογραμμάρια μονοφθοροφωσφορικού και περαιτέρω περιλαμβάνει μία ουσία που περιέχει οιστρογόνο και ένα μηχανισμό βραδείας απελευθέρωσης για ελεγχόμενη απελευθέρωση του ιόντος φθορίου και του οιστρογόνου, σε περίοδο από τέσσερις έως οκτώ ώρες μετά την κατάποση. Μέχρι δέκα τοις εκατό φθοριούχου νατρίου ή/και ασβεστίου μπορεί να προστίθεται. ω
GR910100192A 1990-05-04 1991-05-03 Μεθοδος παρασκευης συνθεσεως για θεραπεια οστεοπορωσης και ορμονικης ανισορροπιας. GR1000989B (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/519,088 US5013728A (en) 1990-05-04 1990-05-04 Composition for treating osteoporosis and hormonal imbalance

Publications (2)

Publication Number Publication Date
GR910100192A GR910100192A (en) 1992-07-30
GR1000989B true GR1000989B (el) 1993-03-31

Family

ID=24066774

Family Applications (1)

Application Number Title Priority Date Filing Date
GR910100192A GR1000989B (el) 1990-05-04 1991-05-03 Μεθοδος παρασκευης συνθεσεως για θεραπεια οστεοπορωσης και ορμονικης ανισορροπιας.

Country Status (12)

Country Link
US (1) US5013728A (el)
EP (1) EP0455503A1 (el)
JP (1) JPH04225921A (el)
AU (1) AU647111B2 (el)
BR (1) BR9101787A (el)
CA (1) CA2041799A1 (el)
FI (1) FI912160A (el)
GR (1) GR1000989B (el)
IE (1) IE911514A1 (el)
MX (1) MX166220B (el)
PT (1) PT97543A (el)
ZA (1) ZA913184B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776493A (en) * 1989-07-14 1998-07-07 Alza Corporation Oral osmotic device for delivery of nystatin with hydrogel driving member
US5153005A (en) * 1990-12-11 1992-10-06 Colgate-Palmolive Company Composition and method for preventing fluorosis
DE59209889D1 (de) * 1991-09-13 2001-03-01 David J Baylink Knochenwachstumsfördernde zusammensetzung
US5795882A (en) * 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
CA2116238C (en) * 1992-06-22 2007-09-04 Joyce C. Knutson Oral 1 .alpha.-hydroxyprevitamin d
US5573776A (en) * 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
ES2173911T3 (es) * 1992-12-29 2002-11-01 Michael F Holick Uso de glicosidos en vitamina d para el tratamiento o prevencion de la osteoporosis.
AU4825200A (en) * 1999-05-07 2000-11-21 Board Of Regents, The University Of Texas System Oral steroidal hormone compositions and methods of use
ES2192136B1 (es) * 2002-01-04 2005-03-16 Italfarmaco, S.A. Composiciones farmaceuticas para el tratamiento o prevencion de la osteoporosis.
US7138394B2 (en) * 2002-09-27 2006-11-21 Alpharx Inc. Vehicle for topical delivery of anti-inflammatory compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3287219A (en) * 1963-08-05 1966-11-22 Charles J Nemanick Method of healing bone fractures
DE2630326C2 (de) * 1976-07-06 1983-07-21 "Gebro" G. Broschek Kg, Chemisch-Pharmazeutische Fabrik, 6391 Fieberbrunn, Tirol Präparat zur Behandlung der Osteoporose und seine Herstellung
US4101668A (en) * 1977-05-10 1978-07-18 Bristol-Myers Company Antiosteoporotic agents
US4185108A (en) * 1977-05-10 1980-01-22 Westwood Pharmaceuticals Inc. Antiosteoporotic agents
IT1106130B (it) * 1977-06-13 1985-11-11 Merck & Co Inc Derivati di 24-deidrovitamina d3 e loro preparazione
US4220552A (en) * 1978-06-05 1980-09-02 The United States Of America As Represented By The Department Of Health, Education & Welfare Method of producing delayed release of sodium fluoride
DE2922671C2 (de) * 1979-06-02 1982-08-19 Battelle-Institut E.V., 6000 Frankfurt Zahnpflege- und Zahnreinigungsmittel
AU532512B2 (en) * 1979-09-07 1983-10-06 Upjohn and Horton Anti-allergenic compounds for bone mineral resorption
FR2542199B1 (fr) * 1983-03-11 1986-01-10 Rizhskij Med Inst Medicament pour le traitement de la carie dentaire
US4726952A (en) * 1983-08-11 1988-02-23 Mission Pharmacal Slow-release sodium fluoride tablet, method of making, and method of treatment of osteoporosis
DE3514583A1 (de) * 1984-04-30 1985-10-31 The Procter & Gamble Co., Cincinnati, Ohio Verwendung eines zwei- oder mehrphasenmittels zur behandlung oder verhinderung von osteoporose
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
GB8521494D0 (en) * 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
US4859467A (en) * 1986-09-25 1989-08-22 Colgate-Palmotive Company Sustained release fluoride composition
US4861590A (en) * 1986-09-25 1989-08-29 Colgate-Palmolive Company Sustained release fluoride and calcium composition
US4795644A (en) * 1987-08-03 1989-01-03 Merck & Co., Inc. Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins
US4814183A (en) * 1987-08-31 1989-03-21 Merck & Co., Inc. Device for the controlled release of drugs with Donnan-like modulation by charged insoluble resins
EP0322020A1 (en) * 1987-12-22 1989-06-28 Akzo N.V. Pharmaceutical dosage unit for treating climacteric complaints and osteoporosis
WO1989009058A1 (en) * 1988-03-25 1989-10-05 Akzo N.V. Pharmaceutical preparation containing a fluoride salt

Also Published As

Publication number Publication date
EP0455503A1 (en) 1991-11-06
US5013728A (en) 1991-05-07
IE911514A1 (en) 1991-11-06
AU647111B2 (en) 1994-03-17
FI912160A0 (fi) 1991-05-03
FI912160A (fi) 1991-11-05
MX166220B (es) 1992-12-23
ZA913184B (en) 1992-12-30
CA2041799A1 (en) 1991-11-05
JPH04225921A (ja) 1992-08-14
PT97543A (pt) 1992-01-31
AU7591491A (en) 1991-11-07
BR9101787A (pt) 1991-12-17
GR910100192A (en) 1992-07-30

Similar Documents

Publication Publication Date Title
YU135980A (en) Process for the manufacture of pharmaceutical formulations in the form of a polyacrylate film
IL99754A0 (en) Pharmaceutical composition for treatment of autoimmune diseases containing an autoantigen or a fragment or analogue thereof
NZ228130A (en) Therapeutic composition comprising fenofibrate and a solid surfactant which has been co-micronised; preparatory process
PL299814A1 (en) Pharmaceutical preparation inhibiting depletion of human bone tissue
NZ231001A (en) Dosage form or composition for administration of an abusable substance to the skin mucosa: permeable substance mixed with non-permeable antagonist
ES2038669T3 (es) Formulacion farmaceutica.
ES509647A0 (es) Procedimiento para preparar una polilactida.
ES2040232T3 (es) Preparaciones medicinales para administracion oral conteniendo una sola dosis de 10 a 240 mg de dihidropiridina.
ATE189400T1 (de) Knochenwachstumsfördernde zusammensetzung
ATE75945T1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
GR1000989B (el) Μεθοδος παρασκευης συνθεσεως για θεραπεια οστεοπορωσης και ορμονικης ανισορροπιας.
NO305581B1 (no) Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose
ES478967A1 (es) Un procedimiento para preparar compuestos de acido 3-cefem-4-carboxilico disustituido en las posiciones 3 y 7.
SE8204874D0 (sv) Farmaceutiska preparat, innefattande humant insulin och humant proinsulin
BR9106676A (pt) Peptideo,processo para promover a liberacao de niveis de hormonio de crescimento em um animal,composicao farmaceutica para promover a liberacao de niveis de hormonio de crescimento em animais,uso do composto e processo para promover a liberacao e elevacao de niveis de hormonio de crescimento no sangue
SE8703632D0 (sv) Sustained release fluoride composition
DE69111974D1 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
OA09121A (fr) Nouveau sel de strontium, son procédé de préparation et les compositions pharmaceutiques le renfermant.
MX9307479A (es) Uso de ciertos derivados de acido metanobisfosfonico en la curacion de fracturas.
NO810480L (no) Anologifremgangsmaate for fremstilling av terapeutisk aktive 1,3,4-oksadiazolylfenol-derivater
JPS5583758A (en) Novel 3*44diazaabicyclo*4*1*0*heptenee*2**onee *5**its manufacture and medicine containing it
ES2042831T3 (es) Procedimiento de preparacion de una composicion farmaceutica para el tratamiento de la osteoporosis.
DE3872881D1 (de) Arzneimittelzusammensetzung zur vorbeugung und behandlung bakterieller und viraler krankheiten.
DE3878154D1 (de) Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid.
EP0018550A3 (en) Use of physiologically acceptable methyl donors in preparing compositions for muscular disease treatment and compositions containing these methyl donors